FDA issues Tussionex safety alert

Mar 11, 2008

The U.S. Food and Drug Administration issued a safety alert, saying incorrect usage of a specific cough medicine can result in serious health risks.

The FDA said its alert concerns the safe and correct use of Tussionex Pennkinetic Extended-Release Suspension -- a prescription cough medicine containing hydrocodone, a narcotic ingredient and the antihistamine chlorpheniramine. The product is approved for use in adults and children over the age of 6 and should be given no more frequently than every 12 hours.

"There is a real and serious risk for overdosing if this medication is not used according to the labeling," said Dr. Curtis Rosebraugh, acting director of the FDA's Office of Drug Evaluation II.

The FDA said adverse event reports associated with Tussionex have included life-threatening side effects and deaths in patients, including children, resulting from taking more than the recommended dose or taking the medication more frequently than every 12 hours.

The federal agency said reports also show Tussionex is sometimes prescribed or given to children younger than 6 years, for whom the medication isn't approved.

Tussionex Pennkinetic Extended-Release Suspension is manufactured by UCB Inc. of Smyrna, Ga.

Copyright 2008 by United Press International

Explore further: Supercomputers link proteins to drug side effects

add to favorites email to friend print save as pdf

Related Stories

Heavy rains leave 22 dead in Nicaragua

43 minutes ago

Days of torrential rains in Nicaragua left 22 people dead and left homeless more than 32,000 others, according to an official report Saturday.

New iPad cellular models have Apple SIM flexibility

57 minutes ago

Cellular-enabled iPad models are under a new paradigm, said AppleInsider, regarding the Apple SIM. Apple's newest iPad models with cellular connectivity use a SIM card which tech sites said could eventually ...

Recommended for you

Supercomputers link proteins to drug side effects

4 hours ago

New medications created by pharmaceutical companies have helped millions of Americans alleviate pain and suffering from their medical conditions. However, the drug creation process often misses many side ...

No added benefit proven for umeclidinium/vilanterol in COPD

11 hours ago

The drug combination umeclidinium/vilanterol (trade name Anoro) has been approved since May 2014 for adults with chronic obstructive pulmonary disease (COPD). In an early benefit assessment pursuant to the Act on the Reform ...

User comments : 0